Orthopaedic Surgery - Chondrosarcoma

Basics

Chondrosarcoma is a primary malignant bone tumor composed of neoplastic cartilage-forming cells within a cartilaginous matrix.

It most commonly involves the pelvis, proximal femur, region around the knee, and spine, although other skeletal sites may also be affected.

Its biologic behavior varies widely depending on histologic subtype and grade.

Tumor Grade and Metastatic Risk

Low-grade, or grade 1, chondrosarcoma has a relatively low metastatic potential, generally less than approximately 5%.

Intermediate-grade, or grade 2, disease carries a higher metastatic risk, commonly around 20–30%.

High-grade or dedifferentiated tumors have a much more aggressive course, with metastatic rates that may approach or exceed 70%.

Mesenchymal chondrosarcoma is also highly aggressive, with a metastatic risk greater than 50%.

Epidemiology

Chondrosarcoma accounts for approximately 20% of primary malignant bone tumors and occurs about half as frequently as osteosarcoma.

It is predominantly a disease of older adults, most often presenting in the sixth through eighth decades of life.

Risk Factors

Important predisposing conditions include hereditary multiple exostoses, Ollier disease, and Maffucci syndrome.

These disorders increase the likelihood of malignant transformation in pre-existing cartilaginous lesions.

Genetics

The genetic basis of chondrosarcoma is heterogeneous and incompletely understood.

Abnormalities involving several chromosomes have been described, including chromosomes 2–11, 14, 15, and 21.

EXT Mutations

Patients with hereditary multiple exostoses caused by an EXT1 mutation appear to have a greater risk of malignant transformation than patients with EXT2 or EXT3 abnormalities.

Myxoid Chondrosarcoma Genetics

Myxoid variants have been associated with a characteristic chromosomal translocation involving chromosomes 9 and 22.

Etiology

Most chondrosarcomas arise de novo, meaning they develop as primary malignant tumors without a known pre-existing lesion.

Others are secondary tumors that develop through malignant transformation of a previously benign cartilage lesion.

Secondary Chondrosarcoma

Secondary chondrosarcoma may arise from a pre-existing osteochondroma or enchondroma.

This is particularly important in patients with hereditary multiple exostoses, Ollier disease, or Maffucci syndrome.

When malignant transformation occurs in these settings, the resulting tumor is often initially low grade.

Dedifferentiated Chondrosarcoma

Dedifferentiated chondrosarcoma accounts for approximately 10% of cases.

It contains a conventional cartilaginous tumor adjacent to a highly malignant noncartilaginous component.

This is one of the most aggressive forms of chondrosarcoma and carries a poor prognosis.

Associated Conditions

Chondrosarcoma is associated particularly with disorders that produce multiple exostoses or enchondromatosis.

Recognition of these underlying conditions is important because changes in pain, lesion size, or imaging appearance may indicate malignant transformation.

Diagnosis

Signs and Symptoms

The typical presentation is deep, gradually progressive pain.

Symptoms may be present for months or even years because many chondrosarcomas grow relatively slowly.

Pain Characteristics

Pain may be worse at night and may persist despite rest.

Unlike many benign musculoskeletal conditions, the discomfort often becomes progressively more constant.

Analgesics or NSAIDs may provide partial relief but usually do not eliminate the symptoms.

Soft-Tissue Mass

With longstanding disease or cortical breakthrough, a palpable soft-tissue mass may develop.

This suggests extension of the tumor beyond the confines of the bone.

History

A high index of suspicion is appropriate when an adult with a known cartilaginous lesion develops new pain, night pain, progressive enlargement, or pain that is no longer relieved by rest.

These features are particularly concerning for malignant transformation.

Physical Examination

The examination is generally nonspecific.

Patients may have tenderness with deep palpation or, in more advanced disease, a palpable soft-tissue mass.

Joint motion may be limited if the tumor is large or located near an articulation.

Laboratory Tests

Routine serum tests are generally not diagnostic.

There are no specific blood markers that reliably establish the diagnosis of chondrosarcoma.

Imaging

Plain Radiographs

Standard AP and lateral radiographs are often highly suggestive of the diagnosis.

The tumor usually appears as an intramedullary lesion containing stippled, ring-like, or arc-shaped calcifications within a cartilaginous matrix.

Cortical Changes

More aggressive lesions may produce substantial cortical abnormalities.

These can include cortical erosion, thickening, expansion, endosteal scalloping, and frank bone destruction.

Chest Imaging

Because chondrosarcoma can metastasize, particularly to the lungs, staging commonly includes chest imaging.

Chest radiographs or, more commonly, CT of the chest may be obtained to evaluate for pulmonary metastases.

MRI

MRI of the affected region is useful for defining the intramedullary extent, cortical involvement, soft-tissue extension, neurovascular relationships, and relationship to nearby joints.

It is also valuable for planning the biopsy approach and surgical resection margins.

Biopsy Planning

The biopsy should be planned carefully because the biopsy tract must usually be removed during definitive tumor resection.

Whenever possible, biopsy planning should be coordinated with the surgeon who will perform the definitive oncologic procedure.

Pathological Findings

Histologic distinction between a benign enchondroma and a well-differentiated low-grade chondrosarcoma can be difficult.

For this reason, pathologic interpretation must be correlated closely with the clinical and radiographic findings.

Trabecular Permeation

A characteristic malignant feature is permeation of pre-existing trabecular bone by the cartilaginous tumor.

This supports an infiltrative rather than expansile benign growth pattern.

Chondroid Matrix

The tumor contains malignant cartilage-producing cells within a chondroid matrix.

Lobulated growth is common.

Cellular Features

Histologic findings may include binucleated chondrocytes, increased cellularity, nuclear atypia, and progressive anaplasia with increasing tumor grade.

Histologic Grading

Conventional chondrosarcomas are usually graded from 1 through 3 according to cellularity, nuclear atypia, mitotic activity, and degree of anaplasia.

Higher grade correlates with a greater risk of metastasis and poorer survival.

Differential Diagnosis

The principal differential diagnoses include enchondroma and bone infarction.

Distinguishing a low-grade chondrosarcoma from an enchondroma can be particularly difficult and often requires integration of symptoms, imaging, and histology.

Treatment

General Measures

Surgery is the mainstay of treatment for conventional chondrosarcoma.

The goal is complete tumor removal with an adequate oncologic margin, thereby minimizing the risk of local recurrence.

Role of Chemotherapy and Radiotherapy

Conventional chondrosarcoma is relatively resistant to both chemotherapy and radiotherapy.

These modalities therefore have a limited role in routine treatment, although selected aggressive subtypes or metastatic disease may be managed differently.

Wide Resection

A wide resection removes the entire tumor together with a surrounding cuff of normal tissue.

This is the standard surgical principle for most intermediate- and high-grade lesions.

Low-Grade Disease

Low-grade lesions may be managed with appropriately selected surgical excision and close radiographic surveillance.

Follow-up commonly includes serial imaging at approximately 6-month intervals during the early surveillance period.

Intermediate- and High-Grade Disease

Patients with grade 2 or 3 chondrosarcoma require more intensive metastatic surveillance.

CT imaging of the chest is commonly performed at regular intervals because the lungs are the most frequent site of metastasis.

Long-Term Surveillance

After approximately 5 years without evidence of disease, follow-up intervals may be increased.

However, long-term surveillance remains important because some chondrosarcomas can recur late.

Physical Therapy

Physical therapy is used after surgery to restore range of motion, strength, gait, and functional independence.

The specific program depends on tumor location and the type of reconstruction performed.

Medication

There is no established medication that reliably treats localized conventional chondrosarcoma.

Patients who develop metastatic disease may receive systemic therapy, but conventional chemotherapy has historically shown limited and inconsistent benefit.

Surgery

Wide resection requires removal of all involved bone and soft tissue while maintaining an adequate margin around the tumor.

The resulting defect may require substantial reconstruction.

Reconstruction

Limb reconstruction can be performed using an allograft, custom prosthesis, modular tumor prosthesis, or other reconstructive technique depending on the site and extent of resection.

Soft-Tissue Reconstruction

Muscle flaps or other reconstructive soft-tissue procedures may be required to cover large defects and protect implants or exposed structures.

Follow-Up

Close postoperative surveillance is required to detect local recurrence, metastasis, or failure of reconstruction.

The intensity of follow-up depends on tumor grade and time since treatment.

Prognosis

Prognosis is strongly determined by histologic grade and subtype.

Low-grade conventional chondrosarcoma generally has an excellent prognosis.

Grade 1 Prognosis

Grade 1 tumors have a metastatic risk of less than approximately 5% and usually have very favorable long-term outcomes when adequately resected.

Grade 2 Prognosis

Grade 2 tumors have a higher metastatic potential, generally below approximately 30%, but overall prognosis remains substantially better than for high-grade disease.

High-Grade and Dedifferentiated Disease

Grades 3 and dedifferentiated tumors carry a poor prognosis because of their high metastatic potential.

Metastatic rates may exceed 70%.

Dedifferentiated Chondrosarcoma Prognosis

Dedifferentiated chondrosarcoma is among the most aggressive subtypes.

Historical series have reported very low long-term survival, with rapid progression once metastatic disease develops.

Mesenchymal Chondrosarcoma

Mesenchymal chondrosarcoma also carries a relatively poor prognosis because of its aggressive behavior and high metastatic potential.

Complications

Important complications include local recurrence, metastatic disease, and failure of reconstruction.

The risk of recurrence rises when surgical margins are inadequate or the tumor is high grade.

Local Recurrence

Local recurrence may result from incomplete resection or microscopic residual disease.

Recurrent tumors can be more difficult to treat and may require additional wide resection or amputation in selected cases.

Metastases

Metastatic spread occurs mainly in intermediate- and high-grade tumors.

The lungs are the most common site, although other organs and bones may also be involved.

Reconstruction Failure

Large oncologic reconstructions can fail because of infection, mechanical loosening, fracture, nonunion, implant failure, or soft-tissue complications.

These problems may require revision surgery.

Patient Monitoring

Patients should initially be reviewed frequently, often at approximately 1–3-month intervals during rehabilitation, depending on the extent of surgery and tumor grade.

Subsequent surveillance should monitor the surgical site, reconstruction, local recurrence, and pulmonary metastases, with imaging intervals adjusted according to oncologic risk.